患者研究伙伴参与风湿病学研究:为2023年更新的EULAR患者研究伙伴参与建议提供依据的系统性文献综述
该系统性文献综述检索PubMed/Medline及网站,纳入2017至2023年发表的53篇文章,评估患者研究伙伴(PRP)参与风湿病学研究的障碍与促进因素。PRP角色从研究伙伴到患者倡导者、顾问和患者审稿人不等,主要障碍为沟通与支持方面的挑战,促进因素包括每个项目配备一名以上PRP、对PRP和研究者进行培训、支持性环境及PRP协调员的存在。
要点
- PRP角色涵盖研究伙伴、患者倡导者、顾问和患者审稿人。
- 32%的文章报告或建议PRP早期参与项目,30%报告或建议参与所有研究阶段。
- 促进因素包括每个项目配备一名以上PRP、培训、支持性环境及PRP协调员。
核心结论
- 该系统性文献综述识别了PRP参与的障碍与促进因素,并为更新欧洲抗风湿病联盟(EULAR)关于PRP与研究者合作建议提供了关键科学证据。
研究设计与样本
- 该系统性文献综述在PubMed/Medline检索2017至2023年发表的关于PRP参与风湿病学研究的文章,并检索风湿病学及其他专科网站。
- 共纳入53篇文章,多数为定性研究(26%)、观点文章(21%)、会议报告(17%)和混合方法研究(11%)。
- 提取关于PRP定义、角色与附加价值以及参与障碍与促进因素的数据,评估文章质量,定量数据描述性分析,定性数据应用主题内容分析原则。
主要发现
- PRP的角色从研究伙伴到患者倡导者、顾问和患者审稿人不等。
- 32%的文章报告或建议PRP早期参与项目,30%报告或建议PRP参与从研究构思阶段到研究结果实施的所有研究阶段。
- 主要障碍是PRP和研究者双方在沟通与支持方面面临的挑战。
- 促进因素包括每个项目配备一名以上PRP、对PRP和研究者进行培训、为PRP提供支持性环境(包括充分的沟通、认可和补偿PRP)以及PRP协调员的存在。
关键数值与推荐
- 原文未报告关键数值与推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient research partners (PRPs) are people with a disease who collaborate in a research team as partners. The aim of this systematic literature review (SLR) was to assess barriers and facilitators to PRP involvement in rheumatology research. METHODS: The SLR was conducted in PubMed/Medline for articles on PRP involvement in rheumatology research, published between 2017 and 2023; websites were also searched in rheumatology and other specialties. Data were extracted regarding the definition of PRPs, their role and added value, as well as barriers and facilitators to PRP involvement. The quality of the articles was assessed. Quantitative data were analysed descriptively, and principles of thematic content analysis was applied to qualitative data. RESULTS: Of 1016 publications, 53 articles were included; the majority of these studies were qualitative studies (26%), opinion articles (21%), meeting reports (17%) and mixed-methods studies (11%). Roles of PRPs ranged from research partners to patient advocates, advisors and patient reviewers. PRPs were reported/advised to be involved early in the project (32% of articles) and in all research phases (30%), from the conception stage to the implementation of research findings. The main barriers were challenges in communication and support for both PRPs and researchers. Facilitators of PRP involvement included more than one PRP per project, training of PRPs and researchers, a supportive environment for PRPs (including adequate communication, acknowledgement and compensation of PRPs) and the presence of a PRP coordinator. CONCLUSION: This SLR identified barriers and facilitators to PRP involvement, and was key to updating the European Alliance of Associations for Rheumatology recommendations for PRP-researcher collaboration based on scientific evidence.
引用
- Aouad K, de Wit M, Elhai M, et al. Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners. Ann Rheum Dis. 2024. PMID: 38724076. doi:10.1136/ard-2024-225567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。